---
title: "Mobile Health on the Rise: Exploring the Regulatory Landscape for Reimbursement"
description: "Digital therapeutics are transforming healthcare, but bringing a DTx solution to patients involves much more than developing the technology. From CE marking and clinical evidence to country-specific reimbursement pathways, the regulatory landscape can quickly become complex. This white paper helps you navigate the requirements for DTx across key European markets, the UK and the US, with a particular focus on the road to reimbursement."
url: https://qbdgroup.com/en/downloads/mobile-health-on-the-rise-exploring-the-regulatory-landscape-for-reimbursement
type: "White paper"
language: en
published: 2024-12-11
publisher: "QbD Group"
citation: "QbD Group, \"Mobile Health on the Rise: Exploring the Regulatory Landscape for Reimbursement\", https://qbdgroup.com/en/downloads/mobile-health-on-the-rise-exploring-the-regulatory-landscape-for-reimbursement"
---
# Mobile Health on the Rise: Exploring the Regulatory Landscape for Reimbursement
> Digital therapeutics are transforming healthcare, but bringing a DTx solution to patients involves much more than developing the technology. From CE marking and clinical evidence to country-specific reimbursement pathways, the regulatory landscape can quickly become complex. This white paper helps you navigate the requirements for DTx across key European markets, the UK and the US, with a particular focus on the road to reimbursement.

Digital therapeutics are transforming healthcare, but bringing a DTx solution to patients involves much more than developing the technology.

From CE marking and clinical evidence to country-specific reimbursement pathways, the regulatory landscape can quickly become complex.

This white paper helps you navigate the requirements for DTx across key European markets, the UK and the US, with a particular focus on the road to reimbursement.

## About This White Paper

Digital Therapeutics (DTx) are gaining ground as clinically validated digital technologies for preventing, managing and treating health conditions. Unlike general health and wellness apps, however, DTx solutions face stringent requirements around clinical evidence, patient safety, data protection and regulatory approval.

And regulatory approval is only part of the journey. For DTx to become truly integrated into healthcare, manufacturers also need to understand how prescription and reimbursement work across different markets.

This white paper provides an overview of that evolving landscape. It explores the European regulatory pathway under the MDR and takes a closer look at reimbursement approaches in Germany, Belgium and France. It then expands the perspective to the UK and US, highlighting the different requirements and pathways DTx manufacturers need to consider when bringing their solutions to market.

## Key Takeaways

✓ **Understand What Sets DTx Apart.** Learn how Digital Therapeutics differ from general health and wellness apps, and why clinical evidence, patient safety, data protection and regulatory approval are central to bringing them into mainstream healthcare.

✓ **Navigate the EU Regulatory Pathway.** Discover how DTx can fall within the scope of the EU MDR, what this means for risk classification, clinical evidence, Quality Management Systems and CE marking, and how classification can affect timelines and costs.

✓ **Explore Germany's DiGA Fast-Track Model.** Understand how Germany combines regulatory requirements with a dedicated prescription and reimbursement pathway, and why early engagement and a Quality by Design approach play an important role in the process.

✓ **Compare Reimbursement Pathways Across Europe.** See how Belgium and France have developed their own approaches to DTx reimbursement and how these compare with Germany's pioneering model. The white paper also provides a broader view of developments across other European markets.

✓ **Understand the Post-Brexit UK Landscape.** Get an overview of CE and UKCA marking, DTAC requirements and NICE evidence standards, including how clinical safety, data protection, security, interoperability and usability factor into market access and reimbursement.

✓ **Get to Grips With the US DTx Pathway.** Explore how the FDA regulates Digital Therapeutics, the role of the Digital Health Center of Excellence and Prescribed Digital Therapeutics, and why FDA clearance does not automatically translate into reimbursement in the US.
---
Source: https://qbdgroup.com/en/downloads/mobile-health-on-the-rise-exploring-the-regulatory-landscape-for-reimbursement — © QbD Group. Quote freely with attribution and a link back.